Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Common Share

Net Loss per Common Share

3 Months Ended

Mar. 31, 2021

13. Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during the period, without consideration for Common Stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and Common Stock equivalents outstanding for the period.

The following shares of potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive for the three months ended March 31, 2021:


	Three Months Ended March 31,
	2021	2020
Warrants to purchase Common Stock	4,579,954	2,653,234
Options to purchase Common Stock	853,490	1,210,502
Unvested Restricted Stock	16,391,786	14,307,564
Unvested Restricted Stock Units	231,926	487,996
Total	22,057,156	18,659,296